Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mentice ABOSTO:MNTC 72 9-Day RSI is 51.05 as of Jul. 15, 2026. GuruFocus rates OSTO:MNTC with a GF Score™ of 72/100 and a GF Value™ of kr26.08 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 869 Medical Devices & Instruments companies, Mentice AB ranks worse than 64.9% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-15), Mentice AB's 9-Day RSI is 51.05.
The industry rank for Mentice AB's 9-Day RSI or its related term are showing as below:
OSTO:MNTC's 9-Day RSI is ranked worse than 64.9% of 869
companies
in the Medical Devices & Instruments industry
Industry Median: 46.12
vs OSTO:MNTC: 51.05
Mentice AB (OSTO:MNTC) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Mentice AB 9-Day RSI Related Terms
OSTO:MNTC vs ABT, SYK, MDT: 9-Day RSI Comparison
For the Medical Devices subindustry, Mentice AB's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mentice AB 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Mentice AB's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mentice AB (OSTO:MNTC) has a 9-Day RSI of 51.05 as of Jul. 15, 2026. According to the industry distribution chart, Mentice AB ranks #564 out of 869 companies in the Medical Devices & Instruments industry, placing it in the top 64.9%.
Is Mentice AB's 9-Day RSI too high?
Mentice AB's current 9-Day RSI is 51.05. The Medical Devices & Instruments industry median 9-Day RSI is 46.12. Mentice AB's value of 51.05 is 10.7% above this industry median. Based on the distribution chart, Mentice AB ranks #564 out of 869 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Mentice AB has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's 9-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #564 out of 869 companies for 9-Day RSI. This places Mentice AB in the lower half of its industry. The industry median 9-Day RSI is 46.12. Mentice AB's value of 51.05 is 10.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 46.12, based on 869 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mentice AB's current 9-Day RSI of 51.05 is 10.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 46.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current 9-Day RSI is 51.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (OSTO:MNTC) is currently considered Possible Value Trap. The stock's GF Value™ is kr26.08, compared to a current price of kr13.15 — trading 49.6% below its estimated fair value. The current 9-Day RSI is 51.05 and 10.7% above the Medical Devices & Instruments industry median of 46.12. Mentice AB's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Mentice AB (OSTO:MNTC), the current 9-Day RSI is 51.05 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (OSTO:MNTC) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of kr13.15 is trading 49.6% below its estimated GF Value™ of kr26.08.
GuruFocus considers Mentice AB to be Possible Value Trap.
Key valuation signals for OSTO:MNTC:
9-Day RSI: 51.05
GF Value™: kr26.08 vs. price of kr13.15 (49.6% below fair value)
Industry Position: 10.7% above the Medical Devices & Instruments median (#564 of 869)
No single metric tells the full story. See the OSTO:MNTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
72GF Score
Get the complete analysis for OSTO:MNTC
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MNTC has been successfully added to your 
